<DOC>
	<DOCNO>NCT01101100</DOCNO>
	<brief_summary>This study open-label extension study 20090062 evaluate extend subcutaneous dose AMG 827 362 week .</brief_summary>
	<brief_title>Study Assess Long-term Safety , Tolerability , Efficacy AMG 827 Subjects With Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subject randomize Study 20090062 complete week 16 evaluation . Subject Serious Adverse Event ( SAE ) report Study 20090062 consider possibly related IP . Subject experience adverse event Study 20090062 , opinion investigator , could cause extension treatment detrimental subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Psoriasis</keyword>
</DOC>